SIMABS
![SIMABS](https://flanders.bio/storage/files/863aeda4-0524-4db3-83d4-35ef8e268e06/company_simabs-2019-logo-black.png)
Agoralaan, Abis Abis /
3590 Diepenbeek
BE
SIMABS
Foundation date
22/08/2019
Sector
#Biotechnology / R&D ServicesSubsector
- #Therapeutics - Biosimilars
- #Therapeutics - Nucleic acid drugs
- #Therapeutics - Proteins
- #R&D Services - Cell culture
- #R&D Services - CMO (Contract Manufacturing Organization)
- #R&D Services - Synthesis services
Therapeutic areas
SIMABS is a start-up biotechnology venture that wants to develop a new bio-manufacturing platform to provide cost effective therapeutic monoclonal antibodies at small scale to biopharmaceutical companies.
Upcoming events
All events-
1109 '24
The Leuven Protein Aggregation Meeting (2nd edition)
Event by: VIB -
1010 '24
-
0411 '24
BIO-Europe® 2024 - 30th Annual International Partnering Conference
Event by: EBD Group
Latest news
More news-
Antonin (Tony) de Fougerolles appointed as new Chair of etherna
Tuesday July 16th 2024
Read more
-
ONTOFORCE Achieves ISO 27001:2022 Certification: A Milestone in Information Security and Trust
Tuesday July 16th 2024
Read more
-
Ghent University spin-off Trince wins Nature Spinoff Prize
Monday July 15th 2024
Read more
Jobs
More jobsMore info?
Ellen Telleir
Communication Coordinator